Brivaracetam efficacy and safety in focal epilepsy

References

• Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475–482.
   PubMed Web of Science ®Google Scholar
• GBD. 2016 epilepsy collaborators. Global, regional, and national burden of epilepsy, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019 Apr;18(4):357–375.
   Web of Science ®Google Scholar
• Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the international league against epilepsy: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58(4):522–530.
   PubMed Web of Science ®Google Scholar
• Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58(4):512–521.
   PubMed Web of Science ®Google Scholar
• Chen Z, Brodie MJ, Liew D, et al. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: A 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3):279–286.
   PubMed Web of Science ®Google Scholar
• Abou-Khalil B. Selecting rational drug combinations in epilepsy. CNS Drugs. 2017;31(10):835–844.
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure. 2000;9(7):464–468.
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Combination therapy in epilepsy: when and what to use. Drugs. 2006;66(14):1817–1829.
   PubMed Web of Science ®Google Scholar
• Margolis JM, Chu BC, Wang ZJ, et al. Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action. JAMA Neurol. 2014;71(8):985–993.
   PubMed Web of Science ®Google Scholar
• Callaghan B, Schlesinger M, Rodemer W, et al. Remission and relapse in a drug-resistant epilepsy population followed prospectively. Epilepsia. 2011;52(3):619–626.
   PubMed Web of Science ®Google Scholar
• Callaghan BC, Anand K, Hesdorffer D, et al. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol. 2007;62(4):382–389.
   PubMed Web of Science ®Google Scholar
• Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs. 2010;70(3):287–312.
   PubMed Web of Science ®Google Scholar
• Klitgaard H, Verdru P. Levetiracetam: the first SV2A ligand for the treatment of epilepsy. Expert Opin Drug Discov. 2007;2(11):1537–1545.
   PubMed Web of Science ®Google Scholar
• Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs? Epilepsia. 2001;42(Suppl 4):13–18.
   PubMed Web of Science ®Google Scholar
• Loscher W, Gillard M, Sands ZA, et al. Synaptic vesicle glycoprotein 2A ligands in the treatment of epilepsy and beyond. CNS Drugs. 2016;30(11):1055–1077.
   PubMed Web of Science ®Google Scholar
• Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology. 2000;55(2):236–242.
   PubMed Web of Science ®Google Scholar
• Shorvon SD, Lowenthal A, Janz D, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European levetiracetam study group. Epilepsia. 2000;41(9):1179–1186.
   PubMed Web of Science ®Google Scholar
• Berkovic SF, Knowlton RC, Leroy RF, et al. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology. 2007;69(18):1751–1760.
   PubMed Web of Science ®Google Scholar
• Noachtar S, Andermann E, Meyvisch P, et al. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology. 2008;70(8):607–616.
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007;68(6):402–408.
   PubMed Web of Science ®Google Scholar
• Rosenow F, Schade-Brittinger C, Burchardi N, et al. The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy–an open-label, prospective, randomised controlled multicenter study. J Neurol Neurosurg Psychiatry. 2012;83(11):1093–1098.
   PubMed Web of Science ®Google Scholar
• Trinka E, Marson AG, Van Paesschen W, et al. KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. J Neurol Neurosurg Psychiatry. 2013;84(10):1138–1147.
   PubMed Web of Science ®Google Scholar
• Noyer M, Gillard M, Matagne A, et al. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol. 1995;286(2):137–146.
   PubMed Web of Science ®Google Scholar
• Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004;101(26):9861–9866.
   PubMed Web of Science ®Google Scholar
• Yang XF, Weisenfeld A, Rothman SM. Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission. Epilepsia. 2007;48(10):1861–1869.
   PubMed Web of Science ®Google Scholar
• Rigo JM, Hans G, Nguyen L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol. 2002;136(5):659–672.
   PubMed Web of Science ®Google Scholar
• Chen B, Choi H, Hirsch LJ, et al. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2017;76:24–31.
   PubMed Web of Science ®Google Scholar
• Klein P, Diaz A, Gasalla T, et al. A review of the pharmacology and clinical efficacy of brivaracetam. Clin Pharmacol. 2018 Jan 19;10:1–22..
   Google Scholar
• Klitgaard H, Matagne A, Nicolas J-M, et al. Brivaracetam: rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. Epilepsia. 2016;57(4):538–548.
   Web of Science ®Google Scholar
• Briviact (brivaracetam) [package insert]. Smyrna, GA: UCB; 2018.
   Google Scholar
• Kaminski RM, Gillard M, Klitgaard H. Targeting SV2A for discovery of antiepileptic drugs. In: Noebels JL, Avoli M, Rogawski MA, et al., editors. Jasper’s basic mechanisms of the epilepsies. th. Bethesda (MD): National Center for Biotechnology Information; 2012. p. 1441–1454.
   Google Scholar
• Bajjalieh SM, Frantz GD, Weimann JM, et al. Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J Neurosci. 1994;14(9):5223–5235.
   PubMed Web of Science ®Google Scholar
• Gronborg M, Pavlos NJ, Brunk I, et al. Quantitative comparison of glutamatergic and GABAergic synaptic vesicles unveils selectivity for few proteins including MAL2, a novel synaptic vesicle protein. J Neurosci. 2010;30(1):2–12.
   PubMed Web of Science ®Google Scholar
• Crowder KM, Gunther JM, Jones TA, et al. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci U S A. 1999;96(26):15268–15273.
   PubMed Web of Science ®Google Scholar
• Janz R, Goda Y, Geppert M, et al. SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release. Neuron. 1999;24(4):1003–1016.
   PubMed Web of Science ®Google Scholar
• Yang X, Bognar J Jr., He T, et al. Brivaracetam augments short-term depression and slows vesicle recycling. Epilepsia. 2015;56(12):1899–1909.
   PubMed Web of Science ®Google Scholar
• Niespodziany I, Andre VM, Leclere N, et al. Brivaracetam differentially affects voltage-gated sodium currents without impairing sustained repetitive firing in neurons. CNS Neurosci Ther. 2015;21(3):241–251.
   PubMed Web of Science ®Google Scholar
• Zona C, Pieri M, Carunchio I, et al. Brivaracetam (ucb 34714) inhibits Na(+) current in rat cortical neurons in culture. Epilepsy Res. 2010;88(1):46–54.
   PubMed Web of Science ®Google Scholar
• Nicolas JM, Hannestad J, Holden D, et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia. 2016;57(2):201–209.
   PubMed Web of Science ®Google Scholar
• Finnema SJ, Rossano S, Naganawa M, et al. A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers. Epilepsia. 2019;60(5):958–967.
   PubMed Web of Science ®Google Scholar
• Matagne A, Margineanu DG, Kenda B, et al. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol. 2008;154(8):1662–1671.
   PubMed Web of Science ®Google Scholar
• Sargentini-Maier ML, Espie P, Coquette A, et al. Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008;36(1):36–45.
   PubMed Web of Science ®Google Scholar
• Mumoli L, Palleria C, Gasparini S, et al. Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures. Drug Des Devel Ther. 2015;9:5719–5725.
   PubMed Web of Science ®Google Scholar
• Stephen LJ, Brodie MJ. Brivaracetam: a novel antiepileptic drug for focal-onset seizures. Ther Adv Neurol Disord. 2018;11:1756285617742081.
   Web of Science ®Google Scholar
• Rolan P, Sargentini-Maier ML, Pigeolet E, et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol. 2008;66(1):71–75.
   PubMed Web of Science ®Google Scholar
• Sargentini-Maier ML, Sokalski A, Boulanger P, et al. Brivaracetam disposition in renal impairment. J Clin Pharmacol. 2012;52(12):1927–1933.
   PubMed Web of Science ®Google Scholar
• Stockis A, Chanteux H, Rosa M, et al. Brivaracetam and carbamazepine interaction in healthy subjects and in vitro. Epilepsy Res. 2015;113:19–27.
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Fakhoury T, McDonough B, et al. Brivaracetam-induced elevation of carbamazepine epoxide levels: A post-hoc analysis from the clinical development program. Epilepsy Res. 2018;145:55–62.
   PubMed Web of Science ®Google Scholar
• Stockis A, Sargentini-Maier ML, Brodie MJ. Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration. Epilepsy Res. 2016;128:163–168.
   PubMed Web of Science ®Google Scholar
• Stockis A, Watanabe S, Scheen AJ. Effect of brivaracetam on CYP3A activity, measured by oral midazolam. J Clin Pharmacol. 2015;55(5):543–548.
   PubMed Web of Science ®Google Scholar
• Stockis A, Watanabe S, Scheen AJ, et al. Effect of rifampin on the disposition of brivaracetam in human subjects: further insights into brivaracetam hydrolysis. Drug Metab Dispos. 2016;44(6):792–799.
   PubMed Web of Science ®Google Scholar
• Nicolas JM, Chanteux H, Rosa M, et al. Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjects. Drug Metab Dispos. 2012;40(8):1466–1472.
   PubMed Web of Science ®Google Scholar
• Stockis A, Rolan P. Effect of brivaracetam (400 mg/day) on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women. J Clin Pharmacol. 2013;53(12):1313–1321.
   PubMed Web of Science ®Google Scholar
• Stockis A, Watanabe S, Fauchoux N. Interaction between brivaracetam (100 mg/day) and a combination oral contraceptive: a randomized, double-blind, placebo-controlled study. Epilepsia. 2014;55(3):e27–31.
   PubMed Web of Science ®Google Scholar
• Asconape JJ. Pharmacokinetic Considerations with the Use of Antiepileptic Drugs in Patients with HIV and Organ Transplants. Curr Neurol Neurosci Rep. 2018;18(12):89.
   PubMed Web of Science ®Google Scholar
• Kruithof AC, Watanabe S, Peeters PA, et al. Pharmacological interactions between brivaracetam and ethanol in healthy males. J Psychopharmacol. 2017;31(7):915–926.
   PubMed Web of Science ®Google Scholar
• Kasteleijn-Nolst Trenite DG, Genton P, Parain D, et al. Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model. Neurology. 2007;69(10):1027–1034.
   PubMed Web of Science ®Google Scholar
• French JA, Costantini C, Brodsky A, et al. Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology. 2010;75(6):519–525.
   PubMed Web of Science ®Google Scholar
• Van Paesschen W, Hirsch E, Johnson M, et al. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia. 2013;54(1):89–97.
   PubMed Web of Science ®Google Scholar
• Biton V, Berkovic SF, Abou-Khalil B, et al. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55(1):57–66.
   PubMed Web of Science ®Google Scholar
• Ryvlin P, Werhahn KJ, Blaszczyk B, et al. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia. 2014;55(1):47–56.
   PubMed Web of Science ®Google Scholar
• Klein P, Schiemann J, Sperling MR, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56(12):1890–1898.
   PubMed Web of Science ®Google Scholar
• Kwan P, Trinka E, Van Paesschen W, et al. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia. 2014;55(1):38–46.
   PubMed Web of Science ®Google Scholar
• Moseley BD, Sperling MR, Asadi-Pooya AA, et al. Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: pooled results from three phase III studies. Epilepsy Res. 2016;127:179–185.
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Whitesides J, Schiemann J, et al. Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: A pooled analysis from three phase III studies. Epilepsy Res. 2016;127:114–118.
   PubMed Web of Science ®Google Scholar
• Klein P, Johnson ME, Schiemann J, et al. Time to onset of sustained >/=50% responder status in patients with focal (partial-onset) seizures in three phase III studies of adjunctive brivaracetam treatment. Epilepsia. 2017;58(2):e21–e25.
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Mameniskiene R, Quarato PP, et al. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Neurology. 2016;87(3):314–323.
   PubMed Web of Science ®Google Scholar
• Toledo M, Whitesides J, Schiemann J, et al. Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures. Epilepsia. 2016;57(7):1139–1151.
   PubMed Web of Science ®Google Scholar
• Abou-Khalil B. Benefit-risk assessment of levetiracetam in the treatment of partial seizures. Drug Saf. 2005;28(10):871–890.
   PubMed Web of Science ®Google Scholar
• Yates SL, Fakhoury T, Liang W, et al. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy Behav. 2015;52(Pt A):165–168.
   PubMed Web of Science ®Google Scholar
• Theochari E, Cock H, Lozsadi D, et al. Brivaracetam in adults with drug-resistant epilepsy and psychiatric comorbidities. Epilepsy Behav. 2018;90:129–131.
   Web of Science ®Google Scholar
• Hirsch M, Hintz M, Specht A, et al. Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: A monocenter retrospective outcome analysis. Seizure. 2018;61:98–103.
   PubMed Web of Science ®Google Scholar
• Steinig I, von Podewils F, Moddel G, et al. Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany. Epilepsia. 2017;58(7):1208–1216.
   PubMed Web of Science ®Google Scholar
• Villanueva V, Lopez-Gonzalez FJ, Mauri JA, et al. BRIVA-LIFE-A multicenter retrospective study of the long-term use of brivaracetam in clinical practice. Acta Neurol Scand. 2019 Apr;139(4):360–368.
   Web of Science ®Google Scholar
• Ortega G, Abraira L, Marti G, et al. Anger assessment in patients treated with brivaracetam. Clin Neuropharmacol. 2018;41(1):6–9.
   PubMed Web of Science ®Google Scholar
• Toledo M, Abraira L, Mazuela G, et al. Effect of brivaracetam on the anger levels of epilepsy patients. A prospective open-labelled controlled study. Seizure. 2019;69:198–203.
   PubMed Web of Science ®Google Scholar
• Witt JA, Elger CE, Helmstaedter C. Short-term and longer-term effects of brivaracetam on cognition and behavior in a naturalistic clinical setting-Preliminary data. Seizure. 2018;62:49–54.
   PubMed Web of Science ®Google Scholar
• Klein P, Biton V, Dilley D, et al. Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy. Epilepsia. 2016;57(7):1130–1138.
   PubMed Web of Science ®Google Scholar
• Andres E, Kerling F, Hamer H, et al. Behavioural changes in patients with intellectual disability treated with brivaracetam. Acta Neurol Scand. 2018;138(3):195–202.
   PubMed Web of Science ®Google Scholar
• Willems LM, Bertsche A, Bosebeck F, et al. Efficacy, retention, and tolerability of brivaracetam in patients with epileptic encephalopathies: a multicenter cohort study from Germany. Front Neurol. 2018;9:569.
   PubMed Web of Science ®Google Scholar
• Schubert-Bast S, Willems LM, Kurlemann G, et al. Postmarketing experience with brivaracetam in the treatment of focal epilepsy in children and adolescents. Epilepsy Behav. 2018;89:89–93.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Kay L, Bauer S, et al. Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus. Epilepsia. 2018;59(8):1549–1556.
   PubMed Web of Science ®Google Scholar
• Kalviainen R, Genton P, Andermann E, et al. Brivaracetam in Unverricht-Lundborg disease (EPM1): results from two randomized, double-blind, placebo-controlled studies. Epilepsia. 2016;57(2):210–221.
   PubMed Web of Science ®Google Scholar
• Kalss G, Rohracher A, Leitinger M, et al. Intravenous brivaracetam in status epilepticus: A retrospective single-center study. Epilepsia. 2018;59(Suppl 2):228–233.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Steinig I, Klein KM, et al. [Brivaracetam for add-on treatment in focal epilepsy]. Nervenarzt. 2016;87(10):1086–1093.
   PubMed Web of Science ®Google Scholar
• Aicua-Rapun I, Andre P, Rossetti AO, et al. Intravenous brivaracetam in status epilepticus: correlation between loading dose, plasma levels and clinical response. Epilepsy Res. 2019;149:88–91.
   PubMed Web of Science ®Google Scholar
• Klein P, Herr D, Pearl PL, et al. Results of phase 2 safety and feasibility study of treatment with levetiracetam for prevention of posttraumatic epilepsy. Arch Neurol. 2012;69(10):1290–1295.
   PubMedGoogle Scholar